Biểu đồ giá cổ phiếu RDHL
RDHL Cổ tức
Redhill Biopharma Ltd
$0.91
-0.98%
$0
Khi đóng cửa: May 20, 16:00:00 GMT-4
$0.9
-2.05%
$-0.01
Phiên trước giờ: May 21, 09:03:38 GMT-4
Quay lại
Redhill Biopharma Ltd (RDHL) Cổ tức
Thống kê chính
Giá đóng cửa trước
$0.9281
Giá mở cửa
$0.91
Phạm vi ngày
$0.9001 - $0.9279
Phạm vi 52 tuần
$0.7101 - $3.3
Khối lượng
58.2K
Khối lượng trung bình
339.7K
Tỷ suất cổ tức
--
EPS (TTM)
-0.00
Vốn hóa thị trường
$4.6M
RDHL là gì?
RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
